Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study

por Strain, W. David, Agarwal, Abhijit S., Paldánius, Päivi M.
Publicado 2017

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia

por Verneris, Michael R., Ma, Qiufei, Zhang, Jie, Keating, Amy, Tiwari, Ranjan, Li, Junlong, Yang, Hongbo, Agarwal, Abhijit, Pacaud, Lida
Publicado 2021

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma

por Maziarz, Richard T., Zhang, Jie, Yang, Hongbo, Chai, Xinglei, Yuan, Chengbo, Schwarz, Elisabeth, Jakovac, Mihael, Martinez-Prieto, Marcela, Agarwal, Abhijit, Degtyarev, Evgeny, Tam, Constantine, Salles, Gilles
Publicado 2022

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

por Jaeger, Ulrich, Tam, Constantine S., Borchmann, Peter, McGuirk, Joseph P., Johansen, Marianne, Waller, Edmund K., Jaglowski, Samantha, Andreadis, Charalambos, Foley, Stephen R., Westin, Jason R., Fleury, Isabelle, Ho, P. Joy, Mielke, Stephan, Teshima, Takanori, Salles, Gilles, Schuster, Stephen J., He, Fiona, Maziarz, Richard T., Mayer, Sebastian, Makita, Shinichi, Kersten, Marie J., Ghosh, Monalisa, Wagner-Johnston, Nina, Kato, Koji, Corradini, Paolo, Goto, Hideki, Colicino, Silvia, Agarwal, Abhijit, Lobetti-Bodoni, Chiara, Bishop, Michael R.
Publicado 2022